Education
About Us
Working with TipRanks
Follow Us
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541)
:1541
Total Valuation
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has a market cap or net worth of HK$5.16B. The enterprise value is HK$4.28B.
Market CapHK$5.16B
Enterprise ValueHK$4.28B
Share Statistics
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has 420,477,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding420,477,300
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -37.81%.
Return on Equity (ROE)-0.47
Return on Assets (ROA)-0.34
Return on Invested Capital (ROIC)-37.81%
Return on Capital Employed (ROCE)-0.44
Revenue Per Employee475.31K
Profits Per Employee-2.03M
Employee Count156
Asset Turnover0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H is ―. ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s PEG ratio is 0.29.
PE Ratio―
PS Ratio24.65
PB Ratio2.69
Price to Fair Value2.69
Price to FCF-13.20
Price to Operating Cash Flow-20.80
PEG Ratio0.29
Income Statement
In the last 12 months, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had revenue of 74.15M and earned -315.86M in profits. Earnings per share was -0.84.
Revenue74.15M
Gross Profit74.15M
Operating Income-308.04M
Pretax Income-316.59M
Net Income-315.86M
EBITDA-295.63M
Earnings Per Share (EPS)-0.84
Cash Flow
In the last 12 months, operating cash flow was -136.13M and capital expenditures -4.75M, giving a free cash flow of -140.89M billion.
Operating Cash Flow-136.13M
Free Cash Flow-140.89M
Free Cash Flow per Share-0.34
Dividends & Yields
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.20
52-Week Price Change29.51%
50-Day Moving Average7.11
200-Day Moving Average9.52
Relative Strength Index (RSI)53.06
Average Volume (3m)4.65M
Important Dates
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H upcoming earnings date is Mar 31, 2026, Before Open (Confirmed).
Last Earnings DateAug 26, 2025
Next Earnings DateMar 31, 2026
Ex-Dividend Date―
Financial Position
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H as a current ratio of 4.04, with Debt / Equity ratio of 28.75%
Current Ratio4.04
Quick Ratio3.93
Debt to Market Cap0.06
Net Debt to EBITDA1.15
Interest Coverage Ratio-89.31
Taxes
In the past 12 months, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H EV to EBITDA ratio is -5.03, with an EV/FCF ratio of -10.74.
EV to Sales20.05
EV to EBITDA-5.03
EV to Free Cash Flow-10.74
EV to Operating Cash Flow-11.61
Balance Sheet
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has HK$703.70M in cash and marketable securities with HK$153.72M in debt, giving a net cash position of HK$549.98M billion.
Cash & Marketable SecuritiesHK$703.70M
Total DebtHK$153.72M
Net CashHK$549.98M
Net Cash Per ShareHK$1.31
Tangible Book Value Per ShareHK$1.80
Margins
Gross margin is 100.00%, with operating margin of -415.44%, and net profit margin of -425.97%.
Gross Margin100.00%
Operating Margin-415.44%
Pretax Margin-426.96%
Net Profit Margin-425.97%
EBITDA Margin-398.70%
EBIT Margin-415.44%
Analyst Forecast
The average price target for ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast29639.67%
EPS Growth Forecast23.30%